Urologie pro praxi 4/2020
Treatment of non-metastatic castration-resistant prostate cancer
Men with non-metastatic castration-resistant prostate cancer with short doubling time PSA are at risk for early disease progression. Results of new clinical studies with antiandrogens II. generations such as apalutamide, enzalutamide, darolutamide have been shown to delay the onset of metastatic disease and prolong survival in these patients.
Keywords: hormone-sensitive diseases, castration resistance, prostate antigen (PSA), non-metastatic castration-resistant prostate cancer, apalutamide, enzalutamide, darolutamide.
